Compare Twist Bioscience Corp (TWST) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Texas Instruments Incorporated — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Texas Instruments Incorporated trades at $260.21 (market cap $236.46B). The key difference: Texas Instruments Incorporated is far larger — about 28.1× Twist Bioscience Corp's market cap, and Texas Instruments Incorporated pays a 2.19% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | TXN | |
|---|---|---|
Market Cap | $8.42B | $236.46B |
Sector | Health | Technology |
52-Week High | $153.10 | $332.35 |
52-Week Low | $24.16 | $153.33 |
Enterprise Value | $8.35B | $243.51B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Texas Instruments (TXN) trades at $261.59, up 1.22% with a bearish technical signal. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026. Revenue growth is recovering from 2024 lows, with 2025 revenue at $17.68B and net income of $5.00B. Analyst consensus is bullish with a $329.74 price target, though technical indicators show resistance near $262.
The outlook remains positive with strong profitability margins and AI-driven demand, but risks include rising debt levels and competitive pressures. The stock offers potential upside from current levels if earnings momentum continues, supported by institutional buy ratings and strategic positioning in analog chips.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
